Management of Adult Sarcoma-AM2018
This didactic session on the management of adult sarcoma will provide a comprehensive overview of adult sarcoma diagnoses and updates in molecular genetic profiling, prognostic factors, treatments and outcomes. It will review practice management with emphasis on multi-modality patient assessment, decision making and the respective roles of radiation therapy, surgery and chemotherapy. Areas of controversy, innovation and active clinical research will also be discussed.
This activity is available from January 11, 2019, through 11:59 p.m. Eastern time on January 10, 2022.
This activity was originally recorded at ASTRO’s 2018 Annual Meeting, October 22-24, 2018 in San Antonio, TX.
The meeting is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists, nurses, radiation therapists, and radiation dosimetrists.
- Describe practice management of adult sarcoma with emphasis on multi-modality patient assessment, decision making, and role of radiation therapy.
- Discuss technical aspects of radiation treatment planning for patients with sarcoma, with updated discussion of studies of outcomes and state of the published data as to what provides the highest value care and best outcomes for patients with sarcoma.
- Discuss new innovations in sarcoma diagnosis and management with emphasis on sarcoma molecular-genetic markers and differential management approaches that provide added value for patients with various presentations of these biologically and anatomically diverse disease processes.
Elizabeth Baldini, MD, MPH is employed by Brigham and Women's Hospital and has nothing to disclose.
Andrew J. Bishop, MD is employed by MD Anderson Cancer Center and has nothing to disclose.
Additionally, the SA-CME Task Force and the CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.